What is claimed is:

1. A method of treating migraine, epilepsy, or bipolar disorder in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I)



(I),

or a pharmaceutically acceptable prodrug thereof, wherein

A is cycloalkyl or bicycloalkyl;

R_A, R_B, and R_C are independently hydrogen or alkyl;

R_1 is OR_2 or NR_3R_4;

R_2 is hydrogen or alkyl;

R_3 and R_4 are independently hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, aryl, arylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, (NR_5R_6)alkyl, (NR_5R_6)carbonylalkyl, or



; or

R_3 and R_4 taken together with the nitrogen atom to which they are attached form a heterocycle wherein the heterocycle is azepanyl, azetidinyl, aziridinyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, or thiomorpholinyl;

R_5 and R_6 are independently hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, or hydroxyalkyl;

R_7 is alkoxy, alkyl, hydroxy, or $-NR_5R_6$;

R_8 is alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkylthioalkyl, alkynyl, aryl, arylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, mercaptoalkyl, (NR_5R_6)alkyl, (NR_5R_6)carbonylalkyl, or $-(CH_2)_nNHC(=NH)NH_2$; and

n is an integer from 1 to 6;

provided that the compound of formula (I) is other than bicyclo[4.1.0]heptane-7-carboxylic acid.

2. The method according to claim 1 wherein

A is cycloalkyl; and

R_1 is OR_2.

3. The method according to claim 1 wherein

A is cycloalkyl wherein the cycloalkyl is optionally substituted with 1 or 2 alkyl groups ; and

R_1 is OR_2.

4. The method according to claim 3 wherein the compound of formula (I) is

3-methylbicyclo[4.1.0]heptane-7-carboxylic acid;

(exo) (1R,2R,4S,5S)-tricyclo[3.2.1.$0^{2,4}$]octane-3-carboxylic acid;

2,4-dimethylbicyclo[4.1.0]heptane-7-carboxylic acid;

(trans) 2,4-dimethylbicyclo[4.1.0]heptane-7-carboxylic acid;

(2S,5R)-2-isopropyl-5-methylbicyclo[4.1.0]heptane-7-carboxylic acid;

(endo) bicyclo[6.1.0]nonane-9-carboxylic acid;

(exo) bicyclo[6.1.0]nonane-9-carboxylic acid;

2,7,7-trimethyltricyclo[4.1.1.$0^{2,4}$]octane-3-carboxylic acid;

1-methylbicyclo[4.1.0]heptane-7-carboxylic acid;

(exo) bicyclo[3.1.0]hexane-6-carboxylic acid;

4,7,7-trimethyltricyclo[4.1.1.$0^{2,4}$]octane-3-carboxylic acid;

3-tert-butylbicyclo[4.1.0]heptane-7-carboxylic acid;

1-methylbicyclo[3.1.0]hexane-6-carboxylic acid; or

1,5-dimethylbicyclo[4.1.0]heptane-7-carboxylic acid.

5. The method according to claim 1 wherein

A is bicycloalkyl; and

R_1 is OR_2.

6. The method according to claim 1 wherein

A is bicycloalkyl wherein the bicycloalkyl is optionally substituted with 1 or 2 alkyl groups; and

R_1 is OR_2.

7. The method according to claim 6 wherein the compound of formula (I) is

(1S,3S,5S,7R)-3,8,8-trimethyltricyclo[5.1.0.$0^{3,5}$]octane-4-carboxylic acid;

(1S,3S,4R,7R)-3,8,8-trimethyltricyclo[5.1.0.$0^{3,5}$]octane-4-carboxylic acid;

(exo) (1aR,2R,2aS,5aR,6S,6aS)-decahydro-2,6-methanocyclopropa[f]indene-1-carboxylic acid;

(1R,5S)-tricyclo[3.3.0.$0^{2,4}$]oct-2(4)-ene-3-carboxylic acid;

octahydro-1H-cyclopropa[a]pentalene-1-carboxylic acid; or

(1R,2R,4R,7R)-4,8,8-trimethyltricyclo[5.1.0.$0^{2,4}$]octane-3-carboxylic acid.

8. The method according to claim 1 wherein

A is cycloalkyl; and

R_1 is NR_3R_4.

9. The method according to claim 1 wherein

A is cycloalkyl wherein the cycloalkyl is optionally substituted with 1 or 2 alkyl groups ;

R_1 is NR_3R_4;

R_3 is hydrogen;

R_4 is hydrogen or (NR_5R_6)carbonylalkyl; and

R_5 and R_6 are hydrogen.

10. The method according to claim 9 wherein the compound of formula (I) is

(exo) (1R,6S)-bicyclo[4.1.0]heptane-7-carboxamide;

(exo) (1R,6S)-N-(2-amino-2-oxoethyl)bicyclo[4.1.0]heptane-7-carboxamide;

3-methylbicyclo[4.1.0]heptane-7-carboxamide;

N-(2-amino-2-oxoethyl)-3-methylbicyclo[4.1.0]heptane-7-carboxamide;

(exo) (1R,2R,4S,5S)-tricyclo[3.2.1.$0^{2,4}$]octane-3-carboxamide;

(exo) (1R,2R,4S,5S)-N-(2-amino-2-oxoethyl)tricyclo[3.2.1.$0^{2,4}$]octane-3-carboxamide;

2,4-dimethylbicyclo[4.1.0]heptane-7-carboxamide;

N-(2-amino-2-oxoethyl)-2,4-dimethylbicyclo[4.1.0]heptane-7-carboxamide;

2,4-dimethylbicyclo[4.1.0]heptane-7-carboxamide;

(1S,2S,4S,6R,7S)-N-(2-amino-2-oxoethyl)-2,4-dimethylbicyclo[4.1.0]heptane-7-carboxamide;

(2S,5R)-2-isopropyl-5-methylbicyclo[4.1.0]heptane-7-carboxamide;

(2S,5R)-N-(2-amino-2-oxoethyl)-2-isopropyl-5-methylbicyclo[4.1.0]heptane-7-carboxamide;

(endo) bicyclo[6.1.0]nonane-9-carboxamide;

(endo) N-(2-amino-2-oxoethyl)bicyclo[6.1.0]nonane-9-carboxamide;

(exo) bicyclo[6.1.0]nonane-9-carboxamide;

(exo) N-(2-amino-2-oxoethyl)bicyclo[6.1.0]nonane-9-carboxamide;

2,7,7-trimethyltricyclo[4.1.1.$0^{2,4}$]octane-3-carboxamide;

N-(2-amino-2-oxoethyl)-2,7,7-trimethyltricyclo[4.1.1.$0^{2,4}$]octane-3-carboxamide;

1-methylbicyclo[4.1.0]heptane-7-carboxamide;

N-(2-amino-2-oxoethyl)-1-methylbicyclo[4.1.0]heptane-7-carboxamide;

(exo) bicyclo[5.1.0]octane-8-carboxamide;

(exo) N-(2-amino-2-oxoethyl)bicyclo[5.1.0]octane-8-carboxamide;

bicyclo[3.1.0]hexane-6-carboxamide;

(exo) N-(2-amino-2-oxoethyl)bicyclo[3.1.0]hexane-6-carboxamide;

4,7,7-trimethyltricyclo[4.1.1.$0^{2,4}$]octane-3-carboxamide;

N-(2-amino-2-oxoethyl)-4,7,7-trimethyltricyclo[4.1.1.$0^{2,4}$]octane-3-carboxamide;

3-tert-butylbicyclo[4.1.0]heptane-7-carboxamide;

N-(2-amino-2-oxoethyl)-3-tert-butylbicyclo[4.1.0]heptane-7-carboxamide;

1-methylbicyclo[3.1.0]hexane-6-carboxamide;

N-(2-amino-2-oxoethyl)-1-methylbicyclo[3.1.0]hexane-6-carboxamide;

1,5-dimethylbicyclo[4.1.0]heptane-7-carboxamide; or

N-(2-amino-2-oxoethyl)-1,5-dimethylbicyclo[4.1.0]heptane-7-carboxamide.

11. The method according to claim 1 wherein

A is bicycloalkyl; and

R_1 is NR_3R_4.

12. The method according to claim 1 wherein

A is bicycloalkyl wherein the bicycloalkyl is optionally substituted with 1 or 2 alkyl groups;

R_1 is NR_3R_4;

R_3 is hydrogen;

R_4 is hydrogen or (NR_5R_6)carbonylalkyl; and

R_5 and R_6 are hydrogen.

13. The method according to claim 12 wherein the compound of formula (I) is

(1S,3S,4S,7R)-3,8,8-trimethyltricyclo[5.1.0.$0^{3,5}$]octane-4-carboxamide;

(1S,3S,4S,7R)-N-(2-amino-2-oxoethyl)-3,8,8-trimethyltricyclo[5.1.0.$0^{3,5}$]octane-4-carboxamide;

(exo) (1aR,2R,2aS,5aR,6S,6aS)-decahydro-2,6-methanocyclopropa[f]indene-1-carboxamide;

(exo) (1aR,2R,2aS,5aR,6S,6aS)-N-(2-amino-2-oxoethyl)decahydro-2,6-methanocyclopropa[f]indene-1-carboxamide;

(1R,5S)-tricyclo[3.3.0.$0^{2,4}$]oct-2(4)-ene-3-carboxamide;

(1R,5S)-N-(2-amino-2-oxoethyl)tricyclo[3.3.0.$0^{2,4}$]oct-2(4)-ene-3-carboxamide;

octahydro-1H-cyclopropa[a]pentalene-1-carboxamide;

N-(2-amino-2-oxoethyl)octahydro-1H-cyclopropa[a]pentalene-1-carboxamide;

(1R,2R,4R,7R)-4,8,8-trimethyltricyclo[5.1.0.$0^{2,4}$]octane-3-carboxamide; or

(1R,2R,4R,7R)-N-(2-amino-2-oxoethyl)-4,8,8-trimethyltricyclo[5.1.0.$0^{2,4}$]octane-3-carboxamide.

14. A method of treating a psychiatric disorder in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).

15. A method of treating pain in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).

16. A method of treating a movement disorder in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).

17. A method of providing neuroprotection in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).

18. A compound of formula (II)



(II),

or a pharmaceutically acceptable prodrug thereof, wherein

A is cycloalkyl or bicycloalkyl;

R_A, R_B, and R_C are independently hydrogen or alkyl;

R_3 is hydrogen or alkyl;

R_4 is alkenyl, alkynyl, alkoxycarbonylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocyclealkyl, hydroxyalkyl, (NR_5R_6)alkyl, (NR_5R_6)carbonylalkyl, or



; or

R_3 and R_4 taken together with the nitrogen atom to which they are attached form a heterocycle wherein the heterocycle is azepanyl, azetidinyl, aziridinyl, morpholinyl, piperazinyl, piperidinyl, pyrrolidinyl, or thiomorpholinyl;

R_5 and R_6 are independently hydrogen, alkenyl, alkyl, alkynyl, alkoxycarbonylalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, or hydroxyalkyl;

R_7 is alkoxy, alkyl, hydroxy, or $-NR_5R_6$;

R_8 is alkenyl, alkoxyalkyl, alkoxycarbonylalkyl, alkylthioalkyl, alkynyl, aryl, arylalkyl, carboxyalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, heterocyclealkyl, hydroxyalkyl, mercaptoalkyl, (NR_5R_6)alkyl, (NR_5R_6)carbonylalkyl, or $-(CH_2)_nNHC(=NH)NH_2$; and

n is an integer from 1 to 6.

19. The compound according to claim 18 wherein A is cycloalkyl.

20. The compound according to claim 18 wherein

A is cycloalkyl wherein the cycloalkyl is optionally substituted with 1 or 2 alkyl groups;

R_3 is hydrogen;

R_4 is (NR_5R_6)carbonylalkyl; and

R_5 and R_6 are hydrogen.

21. The compound according to claim 20 wherein the compound of formula (I) is

(exo) (1R,6S)-N-(2-amino-2-oxoethyl)bicyclo[4.1.0]heptane-7-carboxamide;

N-(2-amino-2-oxoethyl)-3-methylbicyclo[4.1.0]heptane-7-carboxamide;

(exo) (1R,2R,4S,5S)-N-(2-amino-2-oxoethyl)tricyclo[3.2.1.$0^{2,4}$]octane-3-carboxamide;

N-(2-amino-2-oxoethyl)-2,4-dimethylbicyclo[4.1.0]heptane-7-carboxamide;

(1S,2S,4S,6R,7S)-N-(2-amino-2-oxoethyl)-2,4-dimethylbicyclo[4.1.0]heptane-7-carboxamide;

(2S,5R)-N-(2-amino-2-oxoethyl)-2-isopropyl-5-methylbicyclo[4.1.0]heptane-7-carboxamide;

(endo) N-(2-amino-2-oxoethyl)bicyclo[6.1.0]nonane-9-carboxamide;

(exo) N-(2-amino-2-oxoethyl)bicyclo[6.1.0]nonane-9-carboxamide;

N-(2-amino-2-oxoethyl)-2,7,7-trimethyltricyclo[4.1.1.$0^{2,4}$]octane-3-carboxamide;

N-(2-amino-2-oxoethyl)-1-methylbicyclo[4.1.0]heptane-7-carboxamide;

(exo) N-(2-amino-2-oxoethyl)bicyclo[5.1.0]octane-8-carboxamide;

(exo) N-(2-amino-2-oxoethyl)bicyclo[3.1.0]hexane-6-carboxamide;

N-(2-amino-2-oxoethyl)-4,7,7-trimethyltricyclo[4.1.1.$0^{2,4}$]octane-3-carboxamide;

N-(2-amino-2-oxoethyl)-3-tert-butylbicyclo[4.1.0]heptane-7-carboxamide;

N-(2-amino-2-oxoethyl)-1-methylbicyclo[3.1.0]hexane-6-carboxamide; or

N-(2-amino-2-oxoethyl)-1,5-dimethylbicyclo[4.1.0]heptane-7-carboxamide.

22. The compound according to claim 18 wherein A is bicycloalkyl.

23. The compound according to claim 18 wherein

A is bicycloalkyl wherein the bicycloalkyl is optionally substituted with 1 or 2 alkyl groups;

R_3 is hydrogen;

R_4 is (NR_5R_6)carbonylalkyl; and

R_5 and R_6 are hydrogen.

24. The compound according to claim 23 wherein the compound of formula (I) is

(1S,3S,4S,7R)-N-(2-amino-2-oxoethyl)-3,8,8-trimethyltricyclo[5.1.0.$0^{3,5}$]octane-4-carboxamide;

(exo) (1aR,2R,2aS,5aR,6S,6aS)-N-(2-amino-2-oxoethyl)decahydro-2,6-methanocyclopropa[f]indene-1-carboxamide;

(1R,5S)-N-(2-amino-2-oxoethyl)tricyclo[3.3.0.$0^{2,4}$]oct-2(4)-ene-3-carboxamide;

N-(2-amino-2-oxoethyl)octahydro-1H-cyclopropa[a]pentalene-1-carboxamide; or

(1R,2R,4R,7R)-N-(2-amino-2-oxoethyl)-4,8,8-trimethyltricyclo[5.1.0.$0^{2,4}$]octane-3-carboxamide.

25. A method of treating neuropathic and inflammatory pain in a mammal comprising administering to a mammal a therapeutically effective amount of a compound of formula (I).